Ulta Beauty set to kick off annual ’21 Days of Beauty’ event
CHICAGO — Ulta Beauty has announced its top beauty trends for fall 2013 with its annual "21 Days of Beauty" celebration.
The beauty extravaganza kicks off Sept. 8 and ends Sept. 28, and is celebrated in its more than 500 stores nationwide. Each year, Ulta Beauty’s 21 Days of Beauty showcases fall beauty trends with special beauty product offerings alongside makeup and skin care consultations and demonstrations from beauty experts.
Each day Ulta Beauty will feature one "Beauty Steal" and one "Beauty Focus Day" — Beauty Steals are special offers on top beauty products, and Beauty Focus Days feature demonstrations like customized makeup lessons, expert beauty tips and one-on-one appointments. The 21 Days of Beauty participants include such cosmetic and skin care brands as Smashbox, Stila, Tarte, Urban Decay, Benefit and Lorac.
Estée Lauder Cos. taps former L’Oréal USA exec for global corporate responsibility role
NEW YORK — The Estée Lauder Cos. has appointed former L’Oréal USA executive Pamela Gill Alabaster to lead the its global corporate responsibility function.
Alabaster will report to Gregory Polcer, EVP global supply chain and Peter Jueptner, SVP strategy and new business development, co-chairs of the company’s corporate responsibility efforts, under the leadership of executive chairman, William P. Lauder.
Alabaster joins The Estée Lauder Cos. from L’Oréal USA, where she held various senior leadership marketing and management roles, most recently serving as SVP corporate communications, sustainable development and public affairs. In her tenure at L’Oréal USA, Alabaster developed several key corporate functions, including corporate media, public affairs and sustainable development, and led the strategic brand marketing of the L’Oréal Paris and Lancôme brands in the United States.
FDA approves new vial size for CSL Behring immune treatment
KING OF PRUSSIA, Pa. — The Food and Drug Administration has approved a new vial size for a treatment for a rare immune system disorder.
CSL Behring announced the approval of a 10-g, or 50-mL, vial size for Hizentra (immune globulin subcutaneous [human]). The product is used to prevent infections in patients with primary immunodeficiency, and the new vial size will be available in October.
Diseases in the PI group affect about 250,000 people in the United States. The company said the new vial size would help reduce the number of vials patients must use when higher doses are required. Hizentra is already available in 1-g, 2-g and 4-g vials.
"CSL Behring remains dedicated to providing every patient with options that will enhance his or her treatment experience," CSL Behring SVP North America commercial operations Lynne Powell said. "The availability of Hizentra in a 10-g vial will reduce vial preparation for infusion, therefore saving time for both patients and their caregivers."